Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Controlled Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme (GBM)- The C-GBM Study -

NCT01866449 is registered in ClinicalTrials.gov with University of Ulm as lead sponsor.

NCT NCT01866449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01866449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Controlled Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme (GBM)- The C-GBM Study -
Lead sponsor
University of Ulm
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2013
Completion date
August 25, 2017
Enrollment
24 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme (gbm) who grade iv